Doptelet Now Available for Thrombocytopenia in Chronic Liver Disease

Doptelet is a second generation, orally administered TPO receptor agonist
Doptelet is a second generation, orally administered TPO receptor agonist

Dova announced the launch of Doptelet (avatrombopag) for the treatment of thrombocytopenia in adults with chronic liver disease who are undergoing a procedure. 

Doptelet, a second-generation, oral thrombopoietin (TPO) receptor agonist, was initially approved by the Food and Drug Administration (FDA) in May 2018. The drug works by stimulating the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets

Treatment should begin 10 to 13 days before the scheduled procedure at a dose based on platelet count before the procedure; patients should undergo their procedure 5 to 8 days after the last dose. Doptelet should be taken orally once daily for 5 consecutive days with food. Platelet count should be obtained prior to administration and on the day of the procedure to ensure an adequate increase in platelets.

Doptelet has only been investigated in clinical trials as a single 5-day once daily dosing regimen in patients with chronic liver disease. It should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Doptelet is supplied in 20mg tablets in 10- and 15-count cartons and blister cards, which can be ordered through a network of specialty pharmacies. 

Related Articles

For more information call (844) 506-3682 or visit Doptelet.com.